SCLP vs. FARN, FUM, POLB, REDX, ETX, TRX, AREC, 4BB, C4XD, and AVCT
Should you be buying Scancell stock or one of its competitors? The main competitors of Scancell include Faron Pharmaceuticals Oy (FARN), Futura Medical (FUM), Poolbeg Pharma (POLB), Redx Pharma (REDX), e-therapeutics (ETX), Tissue Regenix Group (TRX), Arecor Therapeutics (AREC), 4basebio (4BB), C4X Discovery (C4XD), and Avacta Group (AVCT). These companies are all part of the "biotechnology" industry.
Faron Pharmaceuticals Oy (LON:FARN) and Scancell (LON:SCLP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
In the previous week, Faron Pharmaceuticals Oy and Faron Pharmaceuticals Oy both had 2 articles in the media. Faron Pharmaceuticals Oy's average media sentiment score of 0.34 beat Scancell's score of 0.00 indicating that Scancell is being referred to more favorably in the news media.
Scancell has higher revenue and earnings than Faron Pharmaceuticals Oy. Scancell is trading at a lower price-to-earnings ratio than Faron Pharmaceuticals Oy, indicating that it is currently the more affordable of the two stocks.
13.2% of Faron Pharmaceuticals Oy shares are held by institutional investors. Comparatively, 45.7% of Scancell shares are held by institutional investors. 41.8% of Faron Pharmaceuticals Oy shares are held by insiders. Comparatively, 5.7% of Scancell shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Faron Pharmaceuticals Oy received 130 more outperform votes than Scancell when rated by MarketBeat users. Likewise, 77.51% of users gave Faron Pharmaceuticals Oy an outperform vote while only 74.50% of users gave Scancell an outperform vote.
Scancell's return on equity of 0.00% beat Faron Pharmaceuticals Oy's return on equity.
Faron Pharmaceuticals Oy has a beta of -0.14, meaning that its share price is 114% less volatile than the S&P 500. Comparatively, Scancell has a beta of 0.34, meaning that its share price is 66% less volatile than the S&P 500.
Summary
Scancell beats Faron Pharmaceuticals Oy on 8 of the 13 factors compared between the two stocks.
Get Scancell News Delivered to You Automatically
Sign up to receive the latest news and ratings for SCLP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SCLP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Scancell Competitors List
Related Companies and Tools
